RIT Oncology Overview

  • Founded
  • 2008
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 2

RIT Oncology General Information

Description

Marketer of pharmaceutical preparations. The company commercializes and develops ZEVALIN(R) ([90Y]-ibritumomab tiuxetan), which is a radioimmunotherapeutic drug, used for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma and patients who have rituximab-refractory follicular non-Hodgkin's lymphoma.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 501 Elliott Avenue West
  • Suite 400
  • Seattle, WA 98119
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

RIT Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore RIT Oncology‘s full profile, request access.

Request a free trial

RIT Oncology Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore RIT Oncology‘s full profile, request access.

Request a free trial